JP2006511604A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511604A5
JP2006511604A5 JP2005502468A JP2005502468A JP2006511604A5 JP 2006511604 A5 JP2006511604 A5 JP 2006511604A5 JP 2005502468 A JP2005502468 A JP 2005502468A JP 2005502468 A JP2005502468 A JP 2005502468A JP 2006511604 A5 JP2006511604 A5 JP 2006511604A5
Authority
JP
Japan
Prior art keywords
disorder
sleep
methyl
hydrogen
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005502468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/005684 external-priority patent/WO2004054565A1/en
Publication of JP2006511604A publication Critical patent/JP2006511604A/ja
Publication of JP2006511604A5 publication Critical patent/JP2006511604A5/ja
Withdrawn legal-status Critical Current

Links

JP2005502468A 2002-12-13 2003-12-03 線維筋痛症及び関連する他の障害の治療のためのプレガバリン及びその誘導体 Withdrawn JP2006511604A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
US48348203P 2003-06-27 2003-06-27
PCT/IB2003/005684 WO2004054565A1 (en) 2002-12-13 2003-12-03 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders

Publications (2)

Publication Number Publication Date
JP2006511604A JP2006511604A (ja) 2006-04-06
JP2006511604A5 true JP2006511604A5 (cg-RX-API-DMAC7.html) 2007-10-25

Family

ID=32600152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005502468A Withdrawn JP2006511604A (ja) 2002-12-13 2003-12-03 線維筋痛症及び関連する他の障害の治療のためのプレガバリン及びその誘導体

Country Status (11)

Country Link
US (2) US20040138305A1 (cg-RX-API-DMAC7.html)
EP (1) EP1572187A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006511604A (cg-RX-API-DMAC7.html)
KR (1) KR100845932B1 (cg-RX-API-DMAC7.html)
AU (1) AU2003286300A1 (cg-RX-API-DMAC7.html)
BR (1) BR0317263A (cg-RX-API-DMAC7.html)
CA (1) CA2508297A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006209A (cg-RX-API-DMAC7.html)
PL (1) PL377662A1 (cg-RX-API-DMAC7.html)
TW (1) TW200412939A (cg-RX-API-DMAC7.html)
WO (1) WO2004054565A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
WO2005025563A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
CA2640402C (en) * 2006-03-06 2012-01-03 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
EP1857836B1 (en) * 2006-05-15 2009-10-21 Eldim Sa Device and method for discriminating cerenkov and scintillation radiation
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
CA2710538A1 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
JP5926406B2 (ja) * 2013-01-18 2016-05-25 有限会社ケムフィズ 神経因性疾病の治療のための医薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
EP0934061B3 (en) * 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
NZ334898A (en) * 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
JP2002516312A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα2δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
BR9911887A (pt) * 1998-07-09 2001-03-27 Warner Lambert Co Método para o tratamento da insÈnia
WO2000023067A1 (en) * 1998-10-16 2000-04-27 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
WO2000031020A1 (en) * 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
CZ300834B6 (cs) * 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
AU2002310409C1 (en) * 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system

Similar Documents

Publication Publication Date Title
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
JP2007506801A (ja) モダフィニルおよび他の薬剤を含んでなる製薬学的組成物
RU2336077C2 (ru) Альфа-аминоамидные производные, применимые в качестве антимигренозных средств
WO2007028905A1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
JP6960415B2 (ja) 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用
JP5341037B2 (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用
JP7208139B2 (ja) 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
JP5017268B2 (ja) 覚醒を改善する方法
JP2007503424A (ja) 抗炎症剤として有用なα−アミノアミド誘導体
JP2011088919A (ja) アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物
JP2006516576A5 (cg-RX-API-DMAC7.html)
WO2008004067A2 (en) Alpha-2-delta-1 selective compounds for disorders of the nervous system
JP2024030188A (ja) 女性のうつ症状を改善するための医薬組成物
AU2006209371B2 (en) New association between agomelatine and a thymoregulatory agent, and pharmaceutical compositions containing it
CN101242836A (zh) 改善觉醒状态的方法
HK1093906B (en) Use of agomelatine in obtaining medicaments intended for the treatmemt of bipolar disorders
HK1152661A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
WO2009142588A1 (en) Combination of (a) a chemokine receptor 1 (ccr1) antagonist and (b) glucocorticoid receptor modulator